Boron Cluster Modifications with Antiviral, Anticancer, and Modulation of Purinergic Receptors’ Activities Based on Nucleoside Structures

Adamska‐Bartłomiejczyk, Anna; Bednarska, Katarzyna; Białek‐Pietras, Magdalena; Kiliańska, Zofia M.; Mieczkowski, Adam; Olejniczak, Agnieszka B.; Paradowska, Edyta; Studzińska, Mirosława; Sułowska, Zofia; Żołnierczyk, Jolanta D.; Leśnikowski, Zbigniew J.

doi:10.1002/9781119275602.ch1.2

Cited by 3 publications

(1 citation statement)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metallacarboranes and carboranes have been identified as promising therapeutically important compounds [20][21][22][23][24] including boronated nucleosides that have been extensively studied in recent years [25][26][27][28]. Several approaches have been previously proposed by us for the synthesis of adenosine and 2 -deoxyadenosine derivatives modified with boron clusters (carboranes and metallacarboranes) [29][30][31][32][33][34][35][36][37][38].…”

Section: Introductionmentioning

confidence: 99%

Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance

Bednarska-Szczepaniak

Przelazły

Kania

et al. 2021

Cancers

View full text Add to dashboard Cite

Platinum compounds remain the first-line drugs for the treatment of most lethal gynecological malignancies and ovarian cancers. Acquired platinum resistance remains a major challenge in gynecological oncology. Considering the unique physicochemical properties of the metallacarboranes modifier and the significant role of nucleoside derivatives as anticancer antimetabolites, we designed and synthesized a set of adenosine conjugates with metallacarboranes containing iron, cobalt, or chromium as semi-abiotic compounds that influence the cisplatin sensitivity of ovarian cancer cells. Adherent cultures of ovarian carcinoma cell lines and multicellular spheroids, ranging from sensitive to highly resistant including experimental cell lines “not responding” to platinum drugs were used. Iron-containing metallacarborane conjugates showed the best anticancer activity, especially against resistant cells. Compound modified at the C2′ nucleoside position showed the best activity in resistant cancer cells and highly resistant cancer spheroids exposed to cisplatin, increasing cell cycle arrest, apoptosis or necrosis, and reactive oxygen species production. Moreover, it showed high cellular accumulation and did not induce cross-resistance to cisplatin, carboplatin, doxorubicin, paclitaxel, or gemcitabine in long-term cultures. The reference nido-carborane derivative (no metal ions) and unmodified nucleosides were not as effective. These findings indicate that metallacarborane modification of adenosine may sensitize ovarian cancer cells to cisplatin in combination treatment.

show abstract

Section: Introductionmentioning

confidence: 99%

Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance

Bednarska-Szczepaniak

Przelazły

Kania

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

The disposition of bridge hydrogen bond in the homopolar-diborane and its derivatives

Yadav

Pawar

2023

Computational and Theoretical Chemistry

View full text Add to dashboard Cite

Nanostructured boron agents for boron neutron capture therapy: a review of recent patents

Zhang,

Lin,

Hosmane

et al. 2023

Medical Review

View full text Add to dashboard Cite

Boron neutron capture therapy (BNCT) is a potential radiation therapy modality for cancer, and tumor-targeted stable boron-10 (10B) delivery agents are an important component of BNCT. Currently, two low-molecular-weight boron-containing compounds, sodium mercaptoundecahydro-closo-dodecaborate (BSH) and boronophenylalanine (BPA), are mainly used in BNCT. Although both have suboptimal tumor selectivity, they have shown some therapeutic benefit in patients with high-grade glioma and several other tumors. To improve the efficacy of BNCT, great efforts have been devoted for the development of new boron delivery agents with better uptake and favorable pharmacokinetic profiles. This article reviews the application and research progress of boron nanomaterials as boron carriers in boron neutron capture therapy and hopes to stimulate people’s interest in nanomaterial-based delivery agents by summarizing various kinds of boron nanomaterial patents disclosed in the past decade.

show abstract

Boron Cluster Modifications with Antiviral, Anticancer, and Modulation of Purinergic Receptors’ Activities Based on Nucleoside Structures

Cited by 3 publications

References 50 publications

Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance

Interaction of Adenosine, Modified Using Carborane Clusters, with Ovarian Cancer Cells: A New Anticancer Approach against Chemoresistance

The disposition of bridge hydrogen bond in the homopolar-diborane and its derivatives

Nanostructured boron agents for boron neutron capture therapy: a review of recent patents

Contact Info

Product

Resources

About